# Review: evidence_table.json

**Verdict**: PASS
**Reviewed at**: 2026-04-27T00:00:00Z (re-review post BCS pivot)
**Ledger version**: 2026-04-27T15:09:20.338363Z

## Blockers
- None.

## Non-blocking suggestions
- Row 1 source label reads "Relatório... (GLOBOCAN 2022)" — EV-020's ledger source_file is the strategic report; GLOBOCAN attribution is parenthetical (it appears on EV-006). Verify in Evidence Notes that the GLOBOCAN provenance is traceable for the 750K EU / 36K PT figure (EV-019/EV-020 share the 36K PT estimate; cross-link).
- Row 4 number "SMD -0,68 / -0,49 (139 RCTs, N=19.233)" is dense for the (preencher) text box — verify clean rendering at slide font size. If it wraps awkwardly, drop the (139 RCTs, N=19.233) into Evidence Notes.
- `total_rows: 5` sits in the middle of 4–6. Optional 6th row covering MDR cost/timeline (EV-057 / EV-058) would broaden regulatory framing beyond DiGA. Current set already passes diversity, so this is style, not requirement.

## Checklist Result
| Check | Result |
|---|---|
| 4–6 rows | PASS (5 rows) |
| All EV-IDs resolve in ledger | PASS (EV-020, EV-019, EV-016, EV-023, EV-060 all present) |
| Numbers match ledger | PASS (each row reproduces the ledger entry verbatim or as faithful condensation) |
| aspect_pt ≤ ~50 chars | PASS (43, 37, 41, 44, 41 — all under 50) |
| Diversity: BCS segment size | PASS (EV-020) |
| Diversity: problem magnitude | PASS (EV-019, 30–40% anxiety/depression in BCS) |
| Diversity: access gap | PASS (EV-016, <20% formal psych support) |
| Diversity: DTx outcome precedent | PASS (EV-023, mHealth meta-analysis) |
| Diversity: regulatory/economic (DiGA/MDR) | PASS (EV-060, DiGA reimbursement €200–600/pt/yr) |
| No TBD rows | PASS |
| Plain-text format only (no invented columns) | PASS — `format_note` explicitly declares single (preencher) text box with `Aspecto · Número · Fonte` rendering. JSON is metadata wrapper, not a structured-table claim. |
| No fabrication | PASS |

## Framework Compliance (selected)
| Check | Result |
|---|---|
| Laser focus (BCS only) | PASS — every row is BCS-anchored or directly relevant (DTx precedent, DiGA economics for BT-03 white-label thesis) |
| Personalized to PerSense | PASS — BCS cohort is PerSense's moat segment; DiGA row ties to chosen BT-03 (PT private oncology white-label → DACH/DiGA expansion) |
| No banned bromides | PASS |
| Numbers > adjectives | PASS |

Promote to deliverable-renderer.
